Skip to main content
Top
Published in: Pediatric Rheumatology 1/2023

Open Access 01-12-2023 | Juvenile Dermatomyositis | Research Article

Juvenile dermatomyositis: association between nail fold capillary end row loop– area under the curve– and disease damage indicators

Authors: Amer Khojah, Gabrielle Morgan, Marisa S. Klein-Gitelman, Lauren M. Pachman

Published in: Pediatric Rheumatology | Issue 1/2023

Login to get access

Abstract

Background

Juvenile Dermatomyositis (JDM) is a rare autoimmune disease characterized by skin and muscle inflammation. The loss of nail fold capillary end row loops (ERL) is evidence of small vessel involvement in JDM. This study aimed to examine the specific association of ERL over the disease course with evidence of JDM disease damage.

Methods

We analyzed data from 68 initially treatment-naïve JDM children who had been observed for at least five years with multiple ERL density assessments. The JDM disease course were categorized into monocyclic short, monocyclic long, polycyclic, and chronic. The ERL capillary count was cumulatively evaluated using the area under the curve (AUC) method.

Results

The mean ERL density for the treatment-naive JDM was significantly lower than that of their healthy age-matched controls (4.8 ± 1.6 /mm vs. 7.9 ± 0.9 /mm; p < 0.0001). The ERL AUC was significantly lower in children with a chronic disease course compared to those with a monocyclic short (p = 0.001) or monocyclic long disease course (p = 0.013). JDM patients with lipodystrophy had lower ERL AUC than those without lipodystrophy (p = 0.04). There was no association between ERL AUC and calcifications or fractures.

Conclusion

Persistently decreased ERL capillary density, reflected by low ERL AUC, is associated with a chronic disease course and lipodystrophy in JDM. Despite medical therapy, the mean ERL count remained below normal even after five years, particularly in polycyclic and chronic cases. It is not clear that restoring normal capillary density is currently feasible in children with JDM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pachman LM, Nolan BE, DeRanieri D, Khojah AM. Juvenile Dermatomyositis: New clues to diagnosis and therapy. Curr Treatm Opt Rheumatol. 2021;7(1):39–62.CrossRefPubMedPubMedCentral Pachman LM, Nolan BE, DeRanieri D, Khojah AM. Juvenile Dermatomyositis: New clues to diagnosis and therapy. Curr Treatm Opt Rheumatol. 2021;7(1):39–62.CrossRefPubMedPubMedCentral
2.
go back to reference Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5.CrossRefPubMed Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5.CrossRefPubMed
3.
go back to reference Pachman LM, Khojah AM. Advances in Juvenile Dermatomyositis: Myositis specific antibodies aid in understanding Disease Heterogeneity. J Pediatr. 2018;195:16–27.CrossRefPubMedPubMedCentral Pachman LM, Khojah AM. Advances in Juvenile Dermatomyositis: Myositis specific antibodies aid in understanding Disease Heterogeneity. J Pediatr. 2018;195:16–27.CrossRefPubMedPubMedCentral
4.
go back to reference Costin C, Morgan G, Khojah A, Klein-Gitelman M, Pachman LM. Lower NK cell numbers in children with untreated juvenile Dermatomyositis during the COVID-19 pandemic. Clin Immunol Commun. 2023. Costin C, Morgan G, Khojah A, Klein-Gitelman M, Pachman LM. Lower NK cell numbers in children with untreated juvenile Dermatomyositis during the COVID-19 pandemic. Clin Immunol Commun. 2023.
5.
go back to reference Khojah A, Liu V, Savani SI, Morgan G, Shore R, Bellm J, et al. Association of p155/140 Autoantibody with loss of Nailfold Capillaries but not generalized Lipodystrophy: a study of ninety-six children with Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2022;74(7):1065–9.CrossRefPubMed Khojah A, Liu V, Savani SI, Morgan G, Shore R, Bellm J, et al. Association of p155/140 Autoantibody with loss of Nailfold Capillaries but not generalized Lipodystrophy: a study of ninety-six children with Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2022;74(7):1065–9.CrossRefPubMed
6.
go back to reference Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31(8):1644–9.PubMed Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31(8):1644–9.PubMed
7.
go back to reference Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated Disease in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58(2):571–6.CrossRefPubMedPubMedCentral Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated Disease in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58(2):571–6.CrossRefPubMedPubMedCentral
8.
go back to reference Gibbs EKA, Morgan G, Ehwerhemuepha L, Pachman LM. The Von Willebrand Factor Antigen reflects the Juvenile Dermatomyositis Disease activity score. Biomedicines. 2023;11(2):552.CrossRefPubMedPubMedCentral Gibbs EKA, Morgan G, Ehwerhemuepha L, Pachman LM. The Von Willebrand Factor Antigen reflects the Juvenile Dermatomyositis Disease activity score. Biomedicines. 2023;11(2):552.CrossRefPubMedPubMedCentral
9.
go back to reference Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222–6.CrossRefPubMedPubMedCentral Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222–6.CrossRefPubMedPubMedCentral
10.
go back to reference Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36(7):961–5.CrossRef Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36(7):961–5.CrossRef
11.
go back to reference Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Med (Baltim). 2008;87(2):70–86.CrossRef Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Med (Baltim). 2008;87(2):70–86.CrossRef
12.
go back to reference Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.CrossRef Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.CrossRef
13.
go back to reference Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.CrossRefPubMed Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.CrossRefPubMed
14.
go back to reference Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49(1):7–15.CrossRefPubMed Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49(1):7–15.CrossRefPubMed
15.
go back to reference Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and Patient/Parent global activity, manual muscle testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity score (DAS), short form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), Myositis Functional Index-2 (FI-2), Myositis activities Profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), cutaneous Assessment Tool (CAT), Dermatomyositis skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(0 11):118–57. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and Patient/Parent global activity, manual muscle testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity score (DAS), short form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), Myositis Functional Index-2 (FI-2), Myositis activities Profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), cutaneous Assessment Tool (CAT), Dermatomyositis skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(0 11):118–57.
16.
go back to reference Pachman LM, Morgan G, Klein-Gitelman MS, Ahsan N, Khojah A. Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of Disease activity. Pediatr Rheumatol. 2023;21(1):118.CrossRef Pachman LM, Morgan G, Klein-Gitelman MS, Ahsan N, Khojah A. Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of Disease activity. Pediatr Rheumatol. 2023;21(1):118.CrossRef
17.
go back to reference Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al. Nailfold capillary density is importantly associated over time with muscle and Skin Disease activity in juvenile dermatomyositis. Rheumatology (Oxford). 2011;50(5):885–93.CrossRef Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al. Nailfold capillary density is importantly associated over time with muscle and Skin Disease activity in juvenile dermatomyositis. Rheumatology (Oxford). 2011;50(5):885–93.CrossRef
18.
go back to reference Lim LS, Pullenayegum E, Moineddin R, Gladman DD, Silverman ED, Feldman BM. Methods for analyzing observational longitudinal prognosis studies for rheumatic Diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatr Rheumatol Online J. 2017;15(1):18.CrossRefPubMedCentral Lim LS, Pullenayegum E, Moineddin R, Gladman DD, Silverman ED, Feldman BM. Methods for analyzing observational longitudinal prognosis studies for rheumatic Diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatr Rheumatol Online J. 2017;15(1):18.CrossRefPubMedCentral
19.
go back to reference Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343–62.CrossRefPubMedPubMedCentral Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343–62.CrossRefPubMedPubMedCentral
20.
go back to reference Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, et al. Endothelial activation markers as Disease activity and damage measures in Juvenile Dermatomyositis. J Rheumatol. 2020;47(7):1011–8.CrossRefPubMed Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, et al. Endothelial activation markers as Disease activity and damage measures in Juvenile Dermatomyositis. J Rheumatol. 2020;47(7):1011–8.CrossRefPubMed
21.
go back to reference Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, et al. Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. Rheumatology (Oxford). 2018;57(4):671–6.CrossRefPubMed Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, et al. Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. Rheumatology (Oxford). 2018;57(4):671–6.CrossRefPubMed
22.
go back to reference Yu HH, Chang HM, Chiu CJ, Yang YH, Lee JH, Wang LC, et al. Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis. J Microbiol Immunol Infect. 2016;49(2):264–70.CrossRefPubMed Yu HH, Chang HM, Chiu CJ, Yang YH, Lee JH, Wang LC, et al. Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis. J Microbiol Immunol Infect. 2016;49(2):264–70.CrossRefPubMed
23.
go back to reference Bukhari A, Khojah A, Marin W, Khramtsov A, Khramtsova G, Costin C, et al. Increased otoferlin expression in B cells is Associated with muscle weakness in untreated juvenile dermatomyositis: a pilot study. Int J Mol Sci. 2023;24(13):10553.CrossRefPubMedPubMedCentral Bukhari A, Khojah A, Marin W, Khramtsov A, Khramtsova G, Costin C, et al. Increased otoferlin expression in B cells is Associated with muscle weakness in untreated juvenile dermatomyositis: a pilot study. Int J Mol Sci. 2023;24(13):10553.CrossRefPubMedPubMedCentral
24.
go back to reference Ochfeld E, Hans V, Marin W, Ahsan N, Morgan G, Pachman LM, et al. Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study. BMC Rheumatol. 2022;6(1):36.CrossRefPubMedPubMedCentral Ochfeld E, Hans V, Marin W, Ahsan N, Morgan G, Pachman LM, et al. Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study. BMC Rheumatol. 2022;6(1):36.CrossRefPubMedPubMedCentral
25.
go back to reference Khojah A, Morgan G, Pachman LM. Clues to Disease Activity in Juvenile Dermatomyositis: neopterin and other biomarkers. Diagnostics (Basel). 2021;12(1). Khojah A, Morgan G, Pachman LM. Clues to Disease Activity in Juvenile Dermatomyositis: neopterin and other biomarkers. Diagnostics (Basel). 2021;12(1).
26.
go back to reference McLellan K, Papadopoulou C. Update on biomarkers of Vasculopathy in Juvenile and Adult Myositis. Curr Rheumatol Rep. 2022;24(7):227–37.CrossRefPubMed McLellan K, Papadopoulou C. Update on biomarkers of Vasculopathy in Juvenile and Adult Myositis. Curr Rheumatol Rep. 2022;24(7):227–37.CrossRefPubMed
27.
go back to reference Bloom BJ, Miller LC, Blier PR. Soluble adhesion molecules in pediatric rheumatic Diseases. J Rheumatol. 2002;29(4):832–6.PubMed Bloom BJ, Miller LC, Blier PR. Soluble adhesion molecules in pediatric rheumatic Diseases. J Rheumatol. 2002;29(4):832–6.PubMed
28.
go back to reference Wang A, Khojah A, Morgan G, Pachman LM. Nailfold capillary dropout precedes the presentation of Pneumatosis Intestinalis and micro-perforation in juvenile dermatomyositis. Clin Immunol Commun. 2023;3:74–6.CrossRef Wang A, Khojah A, Morgan G, Pachman LM. Nailfold capillary dropout precedes the presentation of Pneumatosis Intestinalis and micro-perforation in juvenile dermatomyositis. Clin Immunol Commun. 2023;3:74–6.CrossRef
Metadata
Title
Juvenile dermatomyositis: association between nail fold capillary end row loop– area under the curve– and disease damage indicators
Authors
Amer Khojah
Gabrielle Morgan
Marisa S. Klein-Gitelman
Lauren M. Pachman
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2023
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-023-00919-3

Other articles of this Issue 1/2023

Pediatric Rheumatology 1/2023 Go to the issue